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Abstract
Objectives and background: Sleep disorders are common in Parkinson’s Disease 
(PD) occurring in 60% to 98% of patients. Polysomnographic measures showed that 
patients with PD had significantly less total sleep time (TST), less sleep period time, 
increased number of awakenings and wake time after sleep onset (WASO) and, 
consequently, reduced sleep efficiency. The aim of the study was to explore the 
sleep pattern of PD patients, focusing on sleep microstructure by analysing the cyclic 
alternating pattern (CAP).
Methods: Fourteen patients with idiopathic severe PD and fourteen matched 
healthy volunteers were recruited. All subjects underwent overnight polysomnography 
and completed Epworth Sleepiness Scale. Macro- and micro-structural sleep variables 
were evaluated.
Results: Patients with PD had a reduced SE and increased rates of stage shifts 
and awakenings; the N2 and REM sleep percentages were lower and WASO was 
higher in patients. Moreover, patients with PD had lower total CAP rate and lower CAP 
rate in all NREM sleep stages (particularly in N3) than did normal controls. Moreover, 
the analysis of CAP A subtypes distribution showed a decreased A1 percentage in 
patients (more pronounced in N3) and a slight, not significant increase of A3 subtypes.
Conclusions: The total CAP rate is reduced in these patients across all sleep 
stages and this reduction is mainly due to a decrease in CAP A1 subtype. The changes 
in the micro- and macro-structure of sleep could be only partially explained by the 
chronic partial sleep deprivation in PD patients.
INTRODUCTIONSleep disorders are common in Parkinson’s disease (PD) occurring in 60% to 98% of patients [1]. Polysomnographic 
measures showed that patients with PD had significantly less total sleep time (TST), less sleep period time, increased number of awakenings and wake time after sleep onset (WASO) and, 
consequently, reduced sleep efficiency (SE). Sleep-onset latency (SL), and the relative amounts of non rapid eye movements 
(NREM) sleep stage 1 and 2, slow wave sleep (SWS) or rapid 
eye movements (REM) sleep were not significantly different 
between PD patients and age-matched healthy controls. 
Moreover, patients with PD had more frequent abnormal REM 
sleep features and periodic limb movements [2], and an excessive 
daytime sleepiness (EDS) can affect 20-50% of patients with PD 
and correlate with disease severity, higher doses of levodopa, and sometimes the use of dopamine agonists [3]. Arnulf et al. [4] observed that the latency to sleep (measured by multiple sleep 
latency test – MSLT) does not correlate with PSG macrostructural 
measures. Comparing mild versus severe PD patients with EDS, the severity of illness was not associated with changes in sleep 
macrostructural parameters [5]. The conventional coding and macrostructural analysis 
of sleep can underestimate some short-lasting events as the 
arousals. Most authors consider arousals as transient cortical activations in response to sleep disruptive events, usually 
associated with activation of vegetative and somato-motor 
functions. Other slow EEG patterns, such as K-complexes and 
delta burst, are considered as partial form of arousal, a pre-
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Centralactivation heralding the classical arousal, or expression of subcortical arousal. In the realm of periodic activities, the cyclic alternating pattern (CAP) is characterized by sustained periods of cyclical arousability in which arousal events are arranged in a biphasic rhythm of 20-40 s: cyclic sequences of cerebral activation (phase A) are followed by periods of deactivation (phase B). According with the EEG rhythm composition different 
phase A subtypes can be identified: A1 (synchronized events), A2 (mixed synchronized–desynchronized EEG events) and A3 (predominantly desynchronized EEG events).
CAP is present in normal sleepers with specific age-dependent 
modifications, and the slow, rapid and polyphasic patterns of CAP are differently distributed during the descending and ascending slopes of sleep architecture. These observations suggest that CAP, besides being elicited by perturbing factors, could originate from cerebral sources and could play a physiological role in the development of sleep architecture [6].In last years, CAP had been investigated in many different diseases, and among others, narcolepsy [7,8] and attention 
deficit/hyperactivity disorder (ADHD) [9].The present study aims at exploring the sleep pattern of 
severe PD patients, focusing on sleep microstructure by analysing the CAP when compared with healthy volunteers.
SUBJECTS AND METHODSThe study was approved by the local hospital ethics committee.
Among the people with severe PD referred to the Movement 
Disorder Unit of our institution 35 consecutive patients were evaluated. After giving written informed consent, all subjects were interviewed by a neurologist trained in movement disorders 
and a board-certified sleep medicine physician and instructed on the maintenance of sleep logs. Exclusion criteria for all subjects enrolled were major not stabilized medical illnesses, known or suspected history of alcoholism, drug dependence or abuse, other neurological disorders, head trauma and mental disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR), Mini Mental State Examination (MMSE) score <26, diagnosis of dementia 
according to the Movement Disorder Society clinical diagnostic criteria [10], presence of vascular brain lesions, neoplasms and/
or marked cortical and subcortical atrophy at CT and/or MRI scan. Patients were also evaluated through a portable monitoring 
device (Embletta X100, Natus Medical Inc, Pleasanton, CA, USA), monitoring anterior tibialis electromyogram, airflow (nasal-cannula), respiratory effort (thoracic and abdominal), oxygen saturation and cardiac frequency, body position, and snoring. All subjects with sleep related breathing disorders and sleep related 
movement disorders according to International Classification 
of Sleep Disorders III [11] were excluded. Fourteen patients 
(defined “patients”) were recruited and age and gender matched 
with 14 healthy volunteers (defined “controls”).
Each PSG was preceded by an in-laboratory adaptation 
recording to minimize the first-night effect. Video PSG was 
performed by Comet XL Lab-based PSG (Grass Telefactor, Astro-
Med Inc., RI, U.S.A.) by using four EEG channels (C3, C4, O1, 
O2), two electrooculogram channels, chin and anterior tibialis 
electromyogram, electrocardiogram, airflow (nasal-cannula), 
respiratory effort (thoracic and abdominal), oxygen saturation, 
body position, and snoring. After the PSG, subjects rated their 
sleep as the same, worse, or better as compared with usual, and 
completed the Epworth Sleepiness Scale (ESS) [12].PSGs were blindly scored by a sleep technician and interpreted 
by a sleep medicine–certified physician by using standard scoring 
procedures [13,14], while CAP scoring was based on the rules 
defined by Terzano et al. [15]. PSG variables included total sleep 
time (TST), sleep latency (SL), sleep efficiency (SE), REM sleep 
latency, time spent in stages N1, N2, N3 and REM sleep, wake 
time after sleep onset (WASO), number of awakenings, stage 
shifts, apnea–hypopnea index (AHI), respiratory effort related 
arousals (RERAs), and periodic limb-movement index (PLMI). 
The measured microstructural variables were: total CAP time, 
total non-CAP time, CAP rate, non-CAP rate, number, type and 
distribution across sleep stages of A phases (A1, A2, A3).  All of 
these variables were scored through Hypnolab 1.2 sleep software 
analysis (SWS Soft, Italy).
All statistical tests were two-tailed and conducted at a 5% 
significance level. Tests for normality were conducted on all 
continuous data, which were transformed if appropriate. The 
objective parameters were submitted to analysis of variance 
(ANOVA) between-subjects for repeated measures with 
Bonferroni correction. The data analysis software system SPSS 
version 23.0 (IBM SPSS Statistics, US) was used for statistical 
analysis (Table 1).
RESULTS
The table reports the demographic, clinical and sleep macro- 
and micro-structural characteristics of patients and controls. 
Patients with PD had a reduced SE, increased rates of stage shifts 
and awakenings; the S2 and REM sleep percentages were lower, 
and WASO was higher than in controls.
Most patients were on additional treatments: 9/14 with 
dopamine agonists, 8/14 with low doses of benzodiazepines 
(mean daily dose 1.2mg, range 0.5-2.5mg), and 3/14 with low 
doses of atypical neuroleptics (quetiapine; mean daily dose 
25mg).
The polysomnographic monitoring showed loss of the muscle 
atonia during REM sleep in 5/14 patients, two of them met the 
diagnostic criteria for REM sleep Behaviour Disorder. In all 
subjects the AHI and/or RERAs were lower than 5/h and the PLM 
index was lower than 15. Excessive daytime sleepiness (EDS) 
was increased in PD patients, but only in 4 of them ESS score was 
greater than 10.
About the sleep microstructural parameters, patients with PD 
had lower total CAP rate and lower CAP rates in all NREM sleep 
stages (particularly in SWS) than did normal controls. Moreover, 
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Table 1:  Demographic, clinical and macro- and micro-structural polysomnographic variables of patients with severe PD and healthy controls.
  Controls Patients p ≤
  mean SD mean SD
Age (yrs) 64.3 3.1 65.7 3.4 NS
Sex (m/f) 9/5 - 9/5 - -
Hoen & Yahr (stage) - - 3.7 0.8 -
LDOPA (mg) - - 1035 318 -
ESS (score) 4.1 2.6 7.8 3.0 0.001
TIB (min) 527.6 58.9 513.7 96.8 NS
SPT (min) 509.9 58.9 450.1 53.1 0.002
TST (min) 428.9 44.6 288.9 78.6 0.000
SL (min) 17.8 4.1 12.6 15.3 NS
FRL (min) 90.6 13.6 158.8 94.1 .015
Stage shifts (n/h) 7.8 1.4 14.6 5.3 0.001
Awakenings (n/h) 6.0 1.7 8.1 3.2 0.016
SE (%) 84.4 6.3 57.9 18.4 0.000
WASO (%) 14.1 5.5 35.6 18.1 0.001
N1 (%) 9.4 2.6 10.1 5.7 NS
N2 (%) 50.3 4.4 35.5 15.4 0.005
N3 (SWS) (%) 5.9 2.8 8.8 6.7 NS
REM (%) 20.4 4.3 10.0 5.4 0.000
AHI (n/h) 2.9 1.6 2.7 1.3 NS
PLMI (n/h) 4.3 2.1 5.6 2.7 NS
CAP rate tot (%) 56.3 7.1 37.4 21.2 0.007
CAP rate S1 (%) 55.9 8.4 43.8 10.3 0.003
CAP rate S2 (%) 58.9 6.9 41.4 20.0 0.007
CAP rate N3 (SWS) (%) 57.5 7.9 35.5 22.8 0.003
A1 (%) 41.6 11.0 24.2 19.0 0.019
A2 (%) 32.8 10.3 43.6 20.8 NS
A3 (%) 25.6 7.1 32.2 11.7 NS
Abbreviations: LDOPA: Medication Requirement Expressed As Levodopa Equivalent; ESS: Epworth Sleepiness Scale; TIB: Time In Bed; SPT: Sleep 
Period Time; TST: Total Sleep Time; SL: Sleep-Onset Latency; FRL: First REM Latency; SE: Sleep Efficiency; WASO: Wake After Sleep Onset; N1: Nonrem 
Sleep Stage 1; N2: Nonrem Sleep Stage 2; N3: Nonrem Sleep Stage 3; SWS: Slow Wave Sleep; REM: Rapid Eye Movement Sleep; AHI: Apnoea-Hypopnea Index; PLMI: Periodic Limb Movement Index; CAP: Cyclic Alternating Pattern; A1: CAP A1 Subtype; A2: CAP A2 Subtype; A3: CAP A3 Subtypethe analysis of CAP A subtypes distribution showed a decreased 
A1 percentage in patients (more pronounced in SWS) and a slight, 
not significant increase of A3 subtypes. CAP A subtypes index resembled the distribution, showing a decreased A1 subtypes. The duration of A subtypes was similar in patients and controls.
DISCUSSION
To our knowledge, this study represents the first attempt to evaluate CAP in patients with PD and reveals that the total CAP rate is reduced in these patients across all sleep stages, even if 
SWS is more affected. This reduction is mediated by a selective decrease in CAP A1 subtypes. 
Wetter et al [2] reported that the amount of N1 and N2, N3 
(SWS) and REM sleep are similar in PD patients and age matched volunteers. In our study N2 and REM sleep are reduced in PD patients. This difference could be explained by the different 
severity of disease: 2.2 Hoen and Yahr stage in the Wetter’s study, 
3.7 in our case. In fact, our findings regarding the macrostructural parameters resemble those reported in literature in severe PD patients [5]. The differences between patients and controls in micro- and macro-structure of sleep could be explained by the chronic partial sleep deprivation in PD patients. In fact, the sleep deprivation might lead to a higher homeostatic sleep pressure and, therefore, both to an increase in N3 percentage, as to a decrease in total CAP rate consequent to the increase in non-CAP sleep.Some authors [7, 9] found similar CAP changes in ADHD and in narcoleptic patients, and suggested the hypothesis of a 
deficit of the arousal system. Nevertheless, the A1 distribution is different. In fact, A1 subtypes are reduced in light sleep (N1-
N2) and normal in N3 in narcoleptic and ADHD patients, but are 
normal in light sleep and reduced in N3 in PD patients. Taking in 
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Centralaccount that CAP A1 subtypes are involved in the build up and maintenance of deep NREM sleep (N3) and have a protective role for sleep continuity [16], and that N3 percentage is similar in PD patients and in controls, it could be supposed that the decrease of A1 subtypes represents a characteristic feature of PD.Interestingly, in our study, the analysis of the polysomnographic recordings of the four patients with EDS (ESS score > 10) showed that SL, TST, SE are decreased, stage shifts, 
awakenings, WASO and REM sleep percentage are increased when compared with PD patients without EDS (ESS score < 10), while N3 and A1 subtypes percentages are similar in both groups.  It could be speculated that the EDS might be induced by the increase of sleep disruption that cannot be counter balanced 
by a further increase of N3, given the lack of synchronizing effect of A1 subtypes. It has been found that the cortical generators of A1 subtypes 
are localized over the anterior frontal regions, mostly over the midline [17]. The basal forebrain noradrenergic innervation originates in the locus coeruleus (LC), and electrical or chemical stimulation of the LC is effective in shifting the electrocorticogram from low frequency-high amplitude to high frequency-low 
amplitude activity [18]. Intriguingly, Braak et Al [19], staging the brain pathology related to sporadic PD, reported that the coeruleus-subcoeruleus complex is affected even in initial stages of disease.Most of our patients are drug-treated, in particular with 
benzodiazepines (8/14), and they may influence sleep also macro- and micro-structure [20]. In our study the number of 
awakening, the number of stage shift as well as the total amount 
of wake after sleep onset are significantly increased in patients and the CAP rate is reduced (mainly as regards A1 percentage), resembling the sleep pattern observed in insomniac patients 
with abuse of benzodiazepines [21]. These Authors suggested that, in BDZ abusers, the chronic GABAergic stimulation makes 
the thalamic filter less adaptive: when exposed to stimuli, 
abusers either produce no response (and keep sleeping without 
arousal) or fully awaken. As a consequence, abusers have a 
marked reduction of arousals associated with increased number 
of nocturnal awakenings without relevant modifications of sleep macro architecture. Even if the duration of assumption of 
benzodiazepines were similar in both studies (5,2 yrs and 3,5 yrs), the total daily dose was six times lower in our patients (1,2 mg vs 7.8 mg). These data could further support the hypothesis that the arousal system may be dysfunctional in PD patients probably through a degeneration of brainstem structures.
However, these considerations are highly speculative and we should consider some limits of this study. The small sample and the analysis of numerous variables could have introduced 
type-2 errors. Moreover, ESS correlate with patient’s subjective 
sleepiness, but a poor correlation with objective measures has been reported by some authors [22]. Finally, we could not investigate the relationships between CAP decrease, daytime 
sleepiness and Hoehn and Yahr staging, given that only severe PD patients were enrolled. Further studies involving larger number of patients with different stage of disease are needed to validate 
our findings.
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